In the latest development arising from ongoing generic pricing investigations in the US, Taro has admitted to fixing prices, allocating customers and rigging bids for generic medicines, under a conspiracy with multiple firms, including Sandoz.

Complaint names 26 generic dermatologic drug manufacturers and 10 individual executives as defendants, alleging they engaged in a widespread conspiracy to artificially inflate and manipulate prices. State attorneys general say that structural and personnel changes at the companies fostered and facilitated collusion.

More than a dozen claims in a Canadian patent shielding Biogen’s Fampyra treatment for multiple sclerosis have been cut following challenges launched by two generics firms.

While former Sandoz and Heritage execs were charged in the government's generic price-fixing probe, Apotex and its employees will apparently escape such fate if they abide by the terms of DOJ agreement; company admits to fixing price of pravastatin and agrees to pay $24.1m criminal penalty.